explore -WSS

explore

author：knowledge 2025-10-02 11:38:09 - browse：13

Adam's take main illustration — Molly Ferguson/STAT

Cassava Sciences has long claimed its experimental drug, called simufilam, slows the cognitive decline of people with Alzheimer’s. On Friday, we learned how: The company recruited a large number of people into its clinical trial who don’t have Alzheimer’s.

People who almost certainly had Alzheimer’s were also included in the study, but in this group, a placebo outperformed Cassava’s drug.

The conclusion, of course, is obvious: Simufilam is inactive. It’s an inert compound no more effective than a placebo. Cassava’s assertion that simufilam is showing “disease-modifying activity” falls apart given its study was opened to people who should have been ineligible because they were misdiagnosed with Alzheimer’s. Whether that was done intentionally or unwittingly isn’t known, but it’s certainly troubling and makes the case for immediate, regulatory intervention even stronger.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Trump indictment: Who are the 'co

hotspot

WSS

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

No plane should take off without an EpiPen onboard

‘Oppenheimer’ and the risks of AI in health care

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Medicare Advantage overpayments discussion gets experts fired up

explore

explore

hotspot

Bright Health sells Medicare Advantage business to Molina

Fauci's latest grilling in Congress: 9 hours, behind closed doors

Alkermes shareholders re

Hyundai and Kia recall nearly 92,000 vehicles and tell owners to park them outside due to fire risk

Bright Health sells Medicare Advantage business to Molina

Profiling embryos to choose those with higher IQs is almost a reality

The cancer drug shortage isn’t new — and neither are the solutions

The high personal cost of affirmative action for Black doctors

Medicare proposal to cover medical devices draws a mixed reaction

Nonprofit, backed by Microsoft, to certify AI tools in health care

leisure time

Hospital chaplains balance Covid safety with patients’ spiritual needs

Physician assistants need a new name. Here's what it should be

Mega Millions pot grows to $1.25 billion after no winner

5 important ways Henrietta Lacks changed medical science

Mega Millions pot grows to $1.25 billion after no winner

Male doctors called my cancer incurable. A female doctor showed it wasn't

hotspot

explore

entertainment

hotspot